Watching TV for 3 hours daily may up diabetes risk in kids

Agencies
July 31, 2017

London, Jul 31: Parents, take note! Being glued to television or video games for more than three hours a day may put your children at increased risk of developing diabetes, a study warns.

Researchers found that both adiposity, which describes total body fat, and insulin resistance, which occurs when cells fail to respond to insulin, were affected by longer hours of watching television and using computers.

"Our findings suggest that reducing screen time may be beneficial in reducing type 2 diabetes risk factors, in both boys and girls, from an early age," said Claire Nightingale, research fellow at St George's, University of London in the UK.

Researchers based their findings on a sample of nearly 4,500 nine to 10-year-old pupils from 200 primary schools in London, Birmingham and Leicester.

The children were assessed for a series of metabolic and cardiovascular risk factors, including blood fats, insulin resistance, fasting blood glucose levels, blood pressure and body fat.

They were asked about their daily screen time to include TV, computers, and games consoles.

Complete information was obtained for 4,495 (2,337 girls and 2,158 boys) out of the 5,887 who took part in the study between 2004 and 2007; additional data on physical activity was also available for 2,031 of them.

Around a third of the children spent less than an hour of screen time a day, but 28 per cent of the children said they clocked up one to two hours; 13 per cent said their tally was two to three hours; and 18 per cent said they spent more than three hours looking at screens every day.

Trends emerged between screen time and ponderal index—an indicator of weight in relation to height, and skinfolds thickness and fat mass index—indicators of total body fat.

Researchers found that these levels were all higher in children reporting more than three hours of daily screen time than in those who said they spent an hour or less on it.

The team also noted that there was a strong trend between levels of screen time and higher levels of leptin, the hormone that controls appetite, and insulin resistance. The trends remained significant even after taking account of potentially influential factors, including physical activity levels, researchers said.

Previous studies in adults had indicated that spending a lot of time in front of a screen is linked to a heightened risk of weight gain and type 2 diabetes, but until now it has not been clear that children might also be at risk.

"It would be very difficult to carry out this research today as smartphones and tablets are so universal. Children today therefore spend even more time looking at a screen than when the original dataset was taken," Nightingale said. The study was published in the journal Archives of Disease in Childhood.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
May 26,2020

Tedros Adhanom Ghebreyesus, the World Health Organisation's (WHO) Director-General, said that a clinical trial of hydroxychloroquine (HCQ) on COVID-19 patients has come to "a temporary pause", while the safety data of the the anti-malaria drug was being reviewed.

According to the WHO chief, The Lancet medical journal on May 22 had published an observational study on HCQ and chloroquine and its effects on COVID-19 patients that have been hospitalized, reports Xinhua news agency.

The authors of the study reported that among patients receiving the drug, when used alone or with a macrolide, they estimated a higher mortality rate.

"The Executive Group of the Solidarity Trial, representing 10 of the participating countries, met on Saturday (May 23) and has agreed to review a comprehensive analysis and critical appraisal of all evidence available globally," Tedros said in a virtual press conference on Monday.

The review will consider data collected so far in the Solidarity Trial and in particular robust randomized available data, to adequately evaluate the potential benefits and harms from this drug, he said.

"The Executive Group has implemented a temporary pause of the HCQ arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board. The other arms of the trial are continuing," Tedros added.

WHO initiated the Solidarity Trial, a plan to evaluate the safety and efficacy of four drugs and drug combinations against COVID-19 more than two months ago, which include HCQ.

According to the WHO, over 400 hospitals in 35 countries are actively recruiting patients and nearly 3,500 patients have been enrolled from 17 countries under the Solidarity Trial.

Tedros added that the safety concern over the drug related only to the use of HCQ and chloroquine in COVID-19, and "these drugs are accepted as generally safe for use in patients with autoimmune diseases or malaria".

"WHO will provide further updates as we know more," he added.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
July 4,2020

The Union health ministry on Friday revised the dosage of anti-viral drug remdesivir to be administered to coronavirus patients in the moderate stage of illness from the earlier six days to five days as it issued an updated 'Clinical Management Protocols for COVID-19'.

The drug, administered in the form of injection, should be given at a dose of 200 mg on day one followed by 100 mg daily for four days (total five days), the new treatment protocols stated.

The Health Ministry on June 13 had allowed the use of remdesivir for restricted emergency use in moderate cases under "investigational therapies".

"Under emergency use authorisation, remdesivir may be considered for patients in moderate stage requiring oxygen support," the document stated.

It is not recommended for those with severe renal impairment and high level of liver enzymes, pregnant and lactating women, and those below 12 years, it said.

The ministry also okayed off-label application of tocilizumab, a drug that modifies the immune system or its functioning, and convalescent plasma for treating COVID-19 patients in the moderate stage of illness as "investigational therapies".

It also recommended hydroxychloroquine for patients during the early course of the disease and not for critically-ill patients.

On June 27, the ministry had included an inexpensive, widely used steroid dexamethasone in treatment protocols for COVID-19 patients in the moderate to severe stages of their illness among other therapeutic measures.

The ministry advised use of dexamethasone, which is already used in a wide range of conditions for its anti-inflammatory and immunosuppressant effects, as an alternative choice to methylprednisolone for managing moderate to severe cases of coronavirus infection.

India's COVID-19 cases soared by over 20,000 in a day for the first time taking the country's total tally to 6,25,544 on Friday while the death toll climbed to 18,213 with 379 new fatalities, according to the Union Health Ministry data updated at 8 am.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.